Immunovant Stock Total Asset
| IMVT Stock | USD 19.52 0.10 0.51% |
Immunovant fundamentals help investors to digest information that contributes to Immunovant's financial success or failures. It also enables traders to predict the movement of Immunovant Stock. The fundamental analysis module provides a way to measure Immunovant's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunovant stock.
Immunovant |
Immunovant Company Total Asset Analysis
Immunovant's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Immunovant Total Asset | 666.37 M |
Most of Immunovant's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunovant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Immunovant has a Total Asset of 666.37 M. This is 91.14% lower than that of the Biotechnology sector and 66.27% lower than that of the Health Care industry. The total asset for all United States stocks is 97.74% higher than that of the company.
Immunovant Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunovant's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunovant could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics of similar companies.Immunovant is currently under evaluation in total asset category among its peers.
Immunovant Fundamentals
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 2.92 B | ||||
| Shares Outstanding | 169.86 M | ||||
| Shares Owned By Insiders | 58.09 % | ||||
| Shares Owned By Institutions | 47.71 % | ||||
| Number Of Shares Shorted | 14.79 M | ||||
| Price To Book | 9.35 X | ||||
| EBITDA | (269.98 M) | ||||
| Net Income | (259.34 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 138 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 2.40 X | ||||
| Cash Flow From Operations | (214.23 M) | ||||
| Short Ratio | 9.78 X | ||||
| Earnings Per Share | (2.62) X | ||||
| Target Price | 46.92 | ||||
| Number Of Employees | 207 | ||||
| Beta | 0.68 | ||||
| Market Capitalization | 3.32 B | ||||
| Total Asset | 666.37 M | ||||
| Retained Earnings | (825.68 M) | ||||
| Working Capital | 617.16 M | ||||
| Net Asset | 666.37 M |
About Immunovant Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.